| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PLA2G1B |
| Uniprot No | P04054 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 23-148aa |
| 氨基酸序列 | AVWQFRKM IKCVIPGSDP FLEYNNYGCY CGLGGSGTPV DELDKCCQTH DNCYDQAKKL DSCKFLLDNP YTHTYSYSCS GSAITCSSKN KECEAFICNC DRNAAICFSK APYNKAHKNL DTKKYCQS |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于PLA2G1B重组蛋白的代表性文献摘要(基于近年研究趋势虚构，供参考格式)：
1. **文献名称**: *"Recombinant Human PLA2G1B Expression in E. coli and Its Enzymatic Characterization"*
**作者**: Zhang Y et al.
**摘要**: 报道了通过大肠杆菌系统高效表达重组人PLA2G1B蛋白的优化方法，纯化后证实其具有磷脂酶A2活性，并分析其最适pH和温度条件。
2. **文献名称**: *"Structural Insights into PLA2G1B Inhibition by Natural Compounds for Obesity Management"*
**作者**: Lee S et al.
**摘要**: 通过X射线晶体学解析重组PLA2G1B的三维结构，筛选天然化合物抑制其活性，提出其在调节脂质代谢和肥胖治疗中的潜在应用。
3. **文献名称**: *"PLA2G1B Modulates Gut Microbiota via Hydrolysis of Dietary Phospholipids"*
**作者**: Wang X et al.
**摘要**: 利用重组PLA2G1B蛋白探究其在小肠内水解膳食磷脂的作用机制，发现其产物通过改变肠道菌群组成影响宿主代谢炎症反应。
**提示**：实际文献需通过PubMed/Google Scholar检索关键词“PLA2G1B recombinant”获取，建议关注近年发表于*Biochimica et Biophysica Acta (BBA)-Molecular and Cell Biology of Lipids*、*Journal of Lipid Research*等期刊的研究。
Phospholipase A2 group IB (PLA2G1B) is a secreted enzyme belonging to the phospholipase A2 superfamily, which hydrolyzes the sn-2 ester bond of glycerophospholipids to release free fatty acids and lysophospholipids. Initially identified as a pancreatic digestive enzyme, PLA2G1B is synthesized as an inactive preproenzyme that undergoes proteolytic cleavage to generate the mature, catalytically active form. It plays a critical role in lipid digestion by breaking down dietary phospholipids in the intestine. Beyond its physiological function, PLA2G1B has been implicated in various pathological processes, including inflammation, insulin resistance, and metabolic disorders. Elevated levels of PLA2G1B have been associated with obesity, type 2 diabetes, and atherosclerosis, possibly due to its role in generating bioactive lipid mediators that influence cellular signaling and membrane remodeling.
Recombinant PLA2G1B protein is produced using heterologous expression systems, such as E. coli or mammalian cell lines, enabling controlled study of its enzymatic properties and interactions. This engineered protein retains the calcium-dependent catalytic activity of the native enzyme and is widely used to investigate its structure-function relationships, inhibitor screening, and mechanistic roles in disease models. Researchers also utilize recombinant PLA2G1B to explore its potential as a therapeutic target or diagnostic biomarker, particularly in metabolic syndrome-related conditions. Its dual nature—as both a digestive enzyme and a modulator of inflammatory pathways—makes it a subject of interest in bridging nutritional biochemistry and chronic disease research. Recent studies further suggest its involvement in gut microbiota interactions, expanding its relevance to gut-liver axis regulation and systemic metabolism.
×
